Cancer Family
Skin Neoplasm
CI-CAN-00000051Explore in graph →
Non-malignant346 active trials14 approved drugs74 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000051Explore in graph →
Clinical trials
1,424 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06589804 | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | recruiting | Phase 3 | 158 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07068074 | Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma | recruiting | Phase 3 | 428 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 24, 2026 |
| clinicaltrials |
| NCT06585410 | Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | recruiting | Phase 3 | 369 | Regeneron PharmaceuticalsINDUSTRY | 2 | Sep 16, 2026 | clinicaltrials |
| NCT05721755 | Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck | active not recruiting | Phase 3 | 290 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07815574 | iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma(SCOPE Plus) | not yet recruiting | Phase 3 | 550 | Scancell LtdINDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT03233711 | Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer | active not recruiting | Phase 3 | 344 | National Cancer Institute (NCI)NIH | 2 | Sep 10, 2026 | clinicaltrials |
| NCT01274338 | Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery | active not recruiting | Phase 3 | 1,673 | National Cancer Institute (NCI)NIH | 2 | Sep 8, 2026 | clinicaltrials |
| NCT07637734 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)(COVE-3) | recruiting | Phase 3 | 300 | Verrica Pharmaceuticals Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT02339571 | A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma | active not recruiting | Phase 2 / Phase 3 | 600 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02506153 | Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery | active not recruiting | Phase 3 | 1,301 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05063552 | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers | active not recruiting | Phase 2 / Phase 3 | 430 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05634252 | Undergraduate Skin Cancer Prevention Trial(RISE-UP) | active not recruiting | Phase 3 | 528 | University of UtahOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT04799275 | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | active not recruiting | Phase 2 / Phase 3 | 422 | National Cancer Institute (NCI)NIH | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06992427 | High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer(HOPE) | recruiting | Phase 3 | 228 | Alliance for Clinical Trials in OncologyOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07457918 | Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)(COVE-4) | recruiting | Phase 3 | 600 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT06692556 | Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence(SPINO-RT) | recruiting | Phase 3 | 266 | Centre Leon BerardOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06624644 | A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | recruiting | Phase 2 / Phase 3 | 135 | Linnaeus Therapeutics, Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03969004 | Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | active not recruiting | Phase 3 | 415 | Regeneron PharmaceuticalsINDUSTRY | 16 | Mar 27, 2026 | clinicaltrials |
| NCT07381972 | Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma | recruiting | Phase 3 | 142 | University of Sao PauloOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07246590 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)(COVE-2) | recruiting | Phase 3 | 300 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03573401 | Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). | active not recruiting | Phase 3 | 187 | Biofrontera Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07311070 | Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue | enrolling by invitation | Phase 3 | 20 | Daryoush Hamidi Alamdari, PhDOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05786716 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05381597 | 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer | recruiting | Phase 2 / Phase 3 | 200 | Boston UniversityOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07178457 | Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance(BeCALM) | not yet recruiting | Phase 3 | 84 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Sep 17, 2025 | clinicaltrials |
| NCT05860881 | Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)(SiroSkin) | active not recruiting | Phase 3 | 146 | Melanoma and Skin Cancer Trials LimitedOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07152041 | Newly-diagnosed Pediatric Ph-positive B-ALL Protocol(CAMS-Ph+ B-ALL) | recruiting | Phase 3 | 150 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 2 | Sep 3, 2025 | clinicaltrials |
| NCT05955924 | Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial(SPRINTR) | recruiting | Phase 3 | 396 | Women's College HospitalOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05789043 | Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma | recruiting | Phase 3 | 140 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05205902 | TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides(TOTEM-01) | not yet recruiting | Phase 3 | 78 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jan 25, 2022 | clinicaltrials |
Data updated 7 hours agoSource updated Sep 29, 2026source: clinicaltrials